
    
      A Twelve-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Forced Titration,
      Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the
      Pharmacokinetic Profile of 60 mg and 120 mg of GW679769 administered once daily vs Placebo in
      Women with Overactive Bladder
    
  